Brain · Long-term risk
HRT and dementia: what the evidence actually shows
The 'timing hypothesis' explains conflicting HRT-dementia data: estrogen appears neuroprotective when initiated in the perimenopausal window and neutral or harmful when initiated in the mid-60s or later. Observational cohorts and recent Finnish registry data support this framing.
What the data say
- HRT initiated <10 years post-menopause: reduced dementia risk in most cohorts
- HRT initiated in mid-60s: WHIMS showed increased risk with CEE + MPA
- Transdermal estradiol + micronized progesterone: cleanest safety signal
Frequently asked questions
Does HRT prevent Alzheimer's?
Not a proven indication. But early-initiated HRT is associated with reduced dementia incidence in multiple cohorts.
What is the timing hypothesis?
Estrogen is neuroprotective when receptors are intact — early menopause window — and less so once neurodegeneration is underway.
Should I take HRT to prevent dementia?
Prevention is not an FDA indication. But dementia risk should be part of the shared-decision conversation.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.